Basel, Switzerland
Roche, as a global pharmaceutical company, directs its investments towards the development of commercially viable life science companies that yield financial returns, in the field of both medicines and in vitro diagnostics.
76
Total Investments
40
Portfolio Companies
-
Exits
4
Industries
General Information
Industries
Big Data, Biotechnology +2
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Roche Venture Fund
Recent Investments (76)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series B | •••••• | Aug 2026 | |
| Series B | •••••• | May 2025 | |
| Series D | •••••• | Mar 2024 | |
| Late Vc | •••••• | Feb 2024 | |
| Series A | •••••• | Jan 2024 | |
•••• ••••
|
Series A | •••••• | Jan 2024 |
|
•••• ••••
|
Series B | •••••• | Nov 2023 |
|
•••• ••••
|
Grant | •••••• | May 2023 |
|
•••• ••••
|
Series A | •••••• | Nov 2022 |
|
•••• ••••
|
Venture Round | •••••• | Feb 2022 |
Latest News
Glasgow-based Mironid raises €39.9 million in Series B to advance rare kidney disease treatment
Eu-startups · Aug 07, 2026
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.
